- Home
- »
- Healthcare IT
- »
-
U.S. Oncology Information Systems Market Size Report 2035GVR Report cover
U.S. Oncology Information Systems Market (2027 - 2035)
Size, Share & Trends Analysis Report By Products & Services, By Application (Medical Oncology, Surgical Oncology, Radiation Oncology, Surgical Oncology), By End Use And Segment Forecasts
Market Size, 2026
$1.0BMarket Estimate, 2027
$1.1BMarket Forecast, 2035
$2.0BCAGR, 2027–2035
7.7%U.S. Oncology Information Systems Market Summary
The U.S. oncology information systems market was valued at USD 1.0 billion in 2026 and is projected to grow from USD 1.1 billion in 2027 to USD 2.0 billion by 2035, at a CAGR of 7.7% from 2027 to 2035. The growing prevalence of cancer among various demographics and rising demand for advanced innovative oncology information systems (OIS) are some of the driving factors for the U.S. market.
Key Market Trends & Insights
- By product and services: Solutions segment dominated the market with a revenue share of 73.7% in 2026.
- By application: Medical oncology segment dominated the market with a revenue share of 60.0% in 2026.
- By end use: Hospitals & diagnostic imaging centers segment dominated the market with a revenue share of 47.1% in 2026.
Market Size & Forecast
- Market size in 2026: USD 1.0 Billion
- Estimated market size in 2027: USD 1.1 Billion
- Projected market size by 2035: USD 2.0 Billion
- CAGR (2027-2035): 7.7%
Prism AI by Grand View Research Free to tryAsk a question about the U.S. oncology information systems marketTry asking✓Every figure cited from GVR research Prefer the report? Download free sample →
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,Download Free Sample Report
Oncology information solutions deployment is high in hospitals & cancer research institutes in the U.S. due to the rise in the prevalence of cancer and the increase in healthcare expenditure budget.
Market Dynamics
The market is driven by rising cancer incidence, increasing demand for coordinated cancer care, and the growing adoption of digital oncology workflows. Integration of oncology-specific EHRs, treatment planning, imaging, and clinical decision-support tools enables providers to manage complex patient data and support multidisciplinary treatment decisions. However, high implementation and integration costs, legacy-system compatibility challenges, and ongoing maintenance requirements constrain adoption, particularly among smaller oncology providers. Opportunities emerge from AI-enabled oncology workflows, imaging integration, and personalized treatment planning, as vendors expand capabilities to improve clinical efficiency and care coordination.
Cancer treatment increasingly involves combinations of surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapies, requiring coordination across specialties and care settings. For instance, according to the American Cancer Society report published in January 2026, approximately 2.11 million new cancer cases were projected in the U.S., highlighting the substantial volume of patients requiring coordinated diagnosis, treatment, and follow-up.
Cancer care also requires collaboration among oncologists, surgeons, radiologists, pathologists, nurses, pharmacists, and other specialists throughout diagnosis, treatment, and survivorship. According to the American Association for Cancer Research, from July 2025- June 2026, the FDA approved 11 new anticancer therapeutics and expanded the uses of five existing therapies, adding further treatment options and clinical workflows for care teams to manage. These evolving treatment pathways strengthen the need for oncology information systems that support coordinated documentation, treatment planning, and patient data exchange.
Growing Adoption of Precision Oncology and Integrated Clinical Data
Precision oncology increasingly relies on genomic profiling, biomarker testing, and molecular diagnostics to guide treatment selection. Oncology information systems integrate these results into patient records and clinical workflows, helping care teams connect molecular findings with treatment plans and clinical evidence. This integration supports personalized treatment decisions and improves access to relevant patient information across specialties.
For instance, in 2026, CMS set reimbursement for Illumina’s FDA-approved TruSight Oncology Comprehensive test at USD 2,989.55 per test, supporting access to comprehensive genomic profiling. Moreover, in May 2026, the FDA approved Tempus’ tumor-only indication for its xT CDx platform, expanding genomic profiling access when matched normal samples were unavailable. These developments reinforce demand for oncology information systems that integrate molecular results and support data-driven treatment decisions.
Implementing oncology information systems requires substantial investment in software, hardware, interfaces, data migration, staff training, and ongoing maintenance. Integration with existing EHRs, imaging platforms, laboratory systems, and treatment equipment increases technical complexity and implementation costs, creating barriers for smaller oncology providers and community cancer centers.
Cost item
Published estimate
Hardware and software modifications for a radiation oncology EMR
USD 127,000
Staff effort for implementation
More than 1,000 hours
Full-featured hospital-based oncology EMR implementation
USD 1 million-USD 2 million+
Annual software maintenance
Approximately 18% of software license fee
Integrating AI into oncology information systems creates opportunities to improve lesion detection, image analysis, clinical decision support, and treatment planning. By connecting AI tools with patient records, imaging platforms, and oncology treatment workflows, providers can consolidate clinical information, reduce manual tasks, and support more personalized cancer care.
In September 2026, Oracle Health announced its Oncology EHR, designed to integrate oncology-specific workflows, connected patient information, and AI-driven clinical intelligence across diagnosis, treatment, and follow-up. Planned capabilities include unified cancer-care timelines, tumor board preparation, guideline-based treatment planning, and precision oncology insights combining genomic, radiology, pathology, laboratory, and pharmacy data.
“Oracle Health Oncology EHR is designed to bring the patient’s story together and provide personalized treatment recommendations, helping clinicians focus their time and expertise where they matter most: caring for the person in front of them.”
-Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences.
Moreover, in January 2026, Neosoma’s Brain Mets received FDA 510(k) clearance for AI-assisted detection, tracking, and treatment planning for brain metastases. The software automates lesion identification, volumetric measurement, and radiation therapy contouring from MRI scans, and integrates with radiology systems to support neuro-oncology workflows. Brain metastases affect up to 40% of adult cancer patients, underscoring the potential value of AI-enabled imaging integration in oncology care.
AI Integration in the U.S. Oncology Information Systems Market
AI integration is advancing across oncology information systems through clinical documentation automation, patient-data summarization, precision oncology decision support, and imaging analysis. Vendors are embedding AI into EHR and oncology workflows to consolidate fragmented clinical information, support treatment planning, and reduce administrative burden. Adoption is expanding, although implementation in community oncology remains constrained by gaps in training, infrastructure, and reimbursement.
Some of the distinct instances of AI integration in U.S. oncology workflows:
Company / organization
Date
AI integration / development
Mount Sinai Tisch Cancer Center and Triomics
January 2026
Deployed PRISM, an AI-powered clinical trial-matching platform using Triomics’ oncology-specific OncoLLM to identify relevant cancer trials across the health system.
“By deploying an AI platform trained specifically for oncology, we can identify trial opportunities earlier, more consistently, and more equitably, allowing clinicians to focus on meaningful conversations with patients rather than manual chart review.”
- Karyn Goodman, MD, MS, Professor and Vice Chair of Clinical Research
Bristol Myers Squibb and Microsoft
January 2026
Announced a collaboration to deploy FDA-cleared radiology AI algorithms through Microsoft’s Precision Imaging Network to support lung cancer detection from X-ray and CT images.
“By combining Microsoft’s highly scalable radiology solutions with BMS’ deep expertise in oncology and drug delivery, we’ve envisioned a unique AI-enabled workflow that helps clinicians quickly and accurately identify patients with Non-Small Cell Lung Cancer (NSCLC) and guide them to optimal care pathways and precision therapies. An integrated, AI-powered platform that streamlines patient flow can significantly improve operational efficiency and patient outcomes.”
- Alexandra Goncalves, VP and Head of Digital Health, Bristol Myers Squibb.
Tempus AI
June 2025
Expanded Tempus One, its AI clinical assistant, with direct EHR integration to query patient data and support oncology treatment decisions using clinical, molecular, and imaging information.
“This evolution of Tempus One represents a meaningful shift from a world where clinicians spend countless hours searching for answers and documenting care, to one where AI rapidly connects the dots across fragmented systems to deliver actionable insights in real time.”
-Ryan Fukushima, Chief Operating Officer at Tempus.
ASCO and Google Cloud
May 2025
Announced an AI-powered ASCO Guidelines Assistant using Vertex AI and Gemini to help oncology professionals search and interact with evidence-based clinical guidelines.
"Google Cloud's AI expertise is the engine that will drive faster access to critical information, empowering oncology professionals to make rapid, evidence-based decisions for their patients."
-ASCO CEO Clifford Hudis, MD, FACP, FASCO
Market Concentration & Characteristics
The chart below illustrates the relationship between industry concentration, industry characteristics, and industry participants. The X-axis represents the level of market concentration, ranging from low to high. The Y-axis represents various market characteristics, including industry competition, degree of innovation, level of mergers & acquisition activities, regulatory impact, product substitutes, and regional expansion. For instance, the U.S. oncology information systems market is slightly fragmented, with many players entering the market and launching new innovative products.
Innovation in the U.S. oncology information systems market is high, driven by AI-enabled clinical workflows, interoperability, and oncology data analytics. For instance, in June 2025, RaySearch Laboratories released RayCare v2025, adding DICOM Modality Worklist integration, HL7 inbound scheduling, and direct patient-document editing within the patient chart. These enhancements improve data exchange and automate routine oncology workflows.
To learn more about this report,Download Free Sample Report
M&A activity is moderate, as healthcare technology and oncology-focused companies acquire complementary capabilities to expand their platforms and reach. For instance, in March 2026, GE HealthCare completed its USD 2.3 billion acquisition of Intelerad, expanding its enterprise imaging portfolio with cloud-first and AI-enabled software capabilities. This transaction reflects continued consolidation around connected imaging and digital oncology infrastructure
“Intelerad’s cloud-enabled software will support GE HealthCare’s imaging technologies and AI capabilities by simplifying complex workflows, and providing patients and customers with more precise, connected care across the continuum.”
- Roland Rott, President and CEO, Imaging, GE HealthCare.
Government regulations are favoring the growth of the digital health market. The regulations for oncology information systems in the U.S. are primarily focused on protecting Personal Health Information (PHI) and ensuring secure data exchange. In addition, the Office of the National Coordinator for Health Information Technology (ONC) enforces interoperability requirements critical to OIS platforms.
providers are expanding into underserved and regional markets to improve access to cancer diagnosis and treatment, driving demand for interoperable oncology information systems that support distributed care delivery. For instance, in April 2026, Caris Life Sciences reported that its Right-In-Time clinical trial network spanned more than 600 locations across the U.S. and Puerto Rico, connecting community oncology practices with biomarker-driven clinical trials. This expansion highlights the role of connected oncology data and digital workflows in extending specialized cancer services beyond major academic centers.
Analyst Perspective
The U.S. oncology information systems market is evolving as healthcare providers seek more coordinated, efficient, and personalized cancer care. Demand is driven by the need to streamline clinical workflows, integrate patient data across oncology specialties, and support complex treatment decisions. Vendors that deliver interoperable, user-friendly solutions with strong implementation support are well positioned to address the needs of hospitals and specialized cancer centers.
Products & Services Insights
The solutions segment accounted for the largest share of 73.7% in 2026. Its dominance reflects provider demand for integrated software that supports patient information management, treatment planning, clinical documentation, and coordination across oncology workflows. For instance, RaySearch Laboratories’ RayCare integrates oncology information management with treatment planning and radiation therapy workflows, helping providers coordinate patient data and treatment delivery.
The professional services segment is expected to grow at a significant CAGR as oncology providers require specialized support to implement, integrate, customize, and maintain OIS platforms. Services also support staff training, workflow optimization, and interoperability with existing clinical systems. For instance, Elekta provides implementation, training, and support services for its oncology software portfolio, helping healthcare organizations deploy and maintain systems across clinical environments.
Application Insights
The medical oncology segment accounted for the largest share of 60.0% in 2026 and is expected to grow at a fastest CAGR during the forecast period. Growth is supported by the increasing use of chemotherapy, immunotherapy, and targeted therapies, which require coordinated management of treatment regimens, medication schedules, toxicity monitoring, and patient outcomes. For instance, in November 2025, Natera integrated its oncology testing portfolio into OncoEMR, enabling oncologists to order tests and receive results directly within the clinical workflow.
“This integration was designed with their daily workflows in mind-reducing administrative steps and accelerating access to molecular insights that can be used to guide confident treatment decisions.”
-Minetta Liu, M.D., chief medical officer of oncology at Natera.
The surgical oncology segment is expected to witness significant CAGR growth as cancer surgery requires coordinated perioperative documentation, patient tracking, and follow-up care. For isntance, in May 2026, Mount Sinai Tisch Cancer Center presented an electronic patient navigation platform that used pathology and EHR data to identify patients eligible for adjuvant therapy after cancer surgery. Its rule-based approach achieved 95% sensitivity and 99% specificity in identifying eligibility, demonstrating how digital oncology workflows can support post-surgical treatment coordination.
End Use Insights
Based on end use, the hospitals & diagnostic imaging centers segment dominated the market with the largest revenue share of 47.1% in 2026. Hospitals and diagnostic imaging centers rely on oncology information systems to manage cancer-related data, coordinate imaging and treatment workflows, and support collaboration among multidisciplinary care teams. Their established clinical infrastructure and need to manage complex cancer-care pathways support continued demand for integrated oncology software solutions.
To learn more about this report,Download Free Sample Report
The ablation care centers and cancer care centers segment is expected to grow at the fastest CAGR from 2026 to 2033. Medical centers are expanding their cancer services owing to the growing demand for cancer treatment. For instance, in November 2024, UT Southwestern Medical Center announced the expansion of its services in the Fort Worth Medical District by constructing a new USD 177 million radiation oncology campus offering MRI-guided precision radiation treatment. Similarly, in February 2025, Johns Hopkins expanded its surgical oncology services in the Greater Washington Area. Such factors are expected to boost market growth further.
Key U.S. Oncology Information Systems Company Insights
Key players operating in the U.S. oncology information systems market are undertaking various initiatives to strengthen their market presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships play a key role in propelling market growth.
Key U.S. Oncology Information Systems Companies:
-
Elekta AB
-
Accuray Incorporated
-
Varian Medical Systems (Siemens Healthineers)
-
RaySearch Laboratories
-
Cerner Corporation (Oracle Corporation)
-
BrainLab
-
Philips Healthcare
-
Prowess, Inc.
-
DOSIsoft S.A.
-
ViewRay Inc.
-
MIM Software and Flatiron
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Established Players (e.g., Elekta AB, Accuray Incorporated, Varian Medical Systems (Siemens Healthineers), Oracle Health, Brainlab, Philips Healthcare)
- Invest in oncology software innovation and integration with treatment equipment and hospital IT systems.
- Expand through product development, strategic partnerships, and broader clinical platform integration.
- Established customer relationships and broad oncology portfolios.
- Extensive clinical workflow expertise and integration capabilities.
- High implementation and maintenance costs.
- Complex deployment and integration requirements.
Emerging / Specialized Players (e.g., RaySearch Laboratories, Prowess, DOSIsoft, MIM Software, Flatiron Health, ViewRay)
- Focus on specialized workflows such as treatment planning, dose calculation, image processing, and oncology data management.
- Differentiate through targeted innovation, interoperability, and partnerships with larger providers.
- Specialized functionality and focused product development.
- Adaptable workflows and expertise in specific oncology applications.
- Narrower product portfolios and market reach.
- Greater reliance on partnerships or third-party platforms for integration and distribution.
Recent Developments
- In September 2026, Oracle announced Oracle Health Oncology EHR at the Oracle Health and Life Sciences Summit in Orlando, Florida. Built on Oracle’s AI-powered ambulatory EHR, the solution was designed to address the specific needs of cancer care by combining oncology-focused workflows, AI-driven clinical insights from multiple data sources, and connected patient information to support care from diagnosis through treatment and follow-up.
“Oracle Health Oncology EHR is designed to bring the patient’s story together and provide personalized treatment recommendations, helping clinicians focus their time and expertise where they matter most: caring for the person in front of them.”
- Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences.
- In July 2026, Raidium announced the U.S. launch of Raidium Read (R.Read), an AI-powered imaging solution initially targeting oncology research centers. The platform had been deployed at Moffitt Cancer Center, where it replaced a legacy radiomics tool. It offered whole-body lesion detection, AI-based segmentation, and longitudinal lesion tracking across prior and follow-up imaging studies to support complex oncology imaging and clinical research workflows.
"It is transforming and empowering how we conduct oncology clinical research projects, giving our teams a tool designed for the complexity of real-world imaging data."
- Cesar Lam, MD, a radiologist at Moffitt Cancer Center's Diagnostic Imaging and Interventional Radiology Department
- In February 2025, Myriad Genetics partnered with PATHOMIQ to incorporate AI technology into its oncology portfolio, specifically enhancing prostate cancer diagnostics. This partnership includes licensing PATHOMIQ's AI platform, which enhances clinical decision-making by revealing insights from cancer pathology, with plans to launch a AI-driven clinical test later in 2025.
U.S. Oncology Information Systems Market Report Scope
Report Attribute
Details
Market size in 2026
USD 1.0 billion
Estimated market size in 2027
USD 1.1 billion
Projected market size by 2035
USD 2.0 billion
Growth Rate
CAGR of 7.7% from 2027 to 2035
Actual data
2023 - 2025
Forecast period
2027 - 2035
Quantitative units
Revenue in USD million and CAGR from 2027 to 2035
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Products & service, application, end use
Country scope
U.S.
Key companies profiled
Elekta AB; Accuray Incorporated; Varian Medical Systems (Siemens Healthineers); RaySearch Laboratories; Cerner Corporation (Oracle Corporation); BrainLab; Philips Healthcare; Prowess, Inc.; DOSIsoft S.A.; ViewRay Inc.; MIM Software; and Flatiron.
Customization scope
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
U.S. Oncology Information Systems Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2023 to 2035. For this study, Grand View Research has segmented the U.S. oncology information systems market report based on products & service, application, and end use
-
Products & Service Outlook (Revenue, USD Million, 2023 - 2035)
-
Solutions
-
Patient Information Systems
-
Treatment Planning Systems
-
-
Professional Services
-
-
Application Outlook (Revenue, USD Million, 2023 - 2035)
-
Medical Oncology
-
Radiation Oncology
-
Surgical Oncology
-
-
End Use Outlook (Revenue, USD Million, 2023 - 2035)
-
Hospitals & Diagnostic Imaging Centers
-
Ablation Care Centers and Cancer Care Centers
-
Government Institutions
-
Research Facilities
-
Research Methodology
The U.S. oncology information systems market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each U.S. oncology information systems segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment
Segment Definition
By Product & Service:
Solutions
Oncology solutions manages cancer care workflows, including patient records, treatment planning, scheduling, and clinical documentation. It integrates with electronic health records, imaging platforms, and treatment equipment to support coordinated care.
Professional Services
Professional services include implementation, integration, customization, training, technical support, and maintenance of oncology information systems. They help healthcare providers deploy, optimize, and maintain systems within existing clinical workflows.
By Application:
Medical Oncology
Medical oncology systems manage workflows for systemic cancer treatments, including chemotherapy, immunotherapy, and targeted therapy. They support regimen management, medication ordering, dose calculation, scheduling, and treatment monitoring.
Radiation Oncology
Radiation oncology systems manage radiation therapy workflows, including simulation, treatment planning, dose calculation, scheduling, and delivery documentation. They support coordination among radiation oncologists, physicists, dosimetrists, and therapists.
Surgical Oncology
Surgical oncology systems support the planning, coordination, documentation, and follow-up of cancer surgeries. They manage surgical scheduling, preoperative assessments, operative records, pathology information, and postoperative care.
By End Use:
Hospitals & Diagnostic Imaging Centers
These facilities use oncology information systems to coordinate cancer diagnosis, staging, treatment planning, and follow-up. Systems connect oncology records with imaging, laboratory, pathology, and treatment data.
Ablation Care Centers and Cancer Care Centers
Specialized centers use oncology information systems to manage patient assessments, treatment planning, procedure documentation, and follow-up. Systems support coordination among oncology specialists and longitudinal patient record management.
Government Institutions
Government healthcare institutions use oncology information systems to manage patient records, treatment workflows, and cancer care reporting. These systems support coordination across public healthcare networks, quality monitoring, and research.
Research Facilities
Research facilities use oncology information systems to organize clinical data for cancer research, clinical trials, and outcomes analysis. Systems support patient cohort identification, research documentation, and integration with research databases.
Estimation Model
The market size of the U.S. oncology information systems market was estimated using a bottom-up approach, supported by company-level revenue analysis, product benchmarking, and segment-level revenue estimation. Key market participants were identified, and their AI-based products and integrated solutions were benchmarked to assess their presence in the market. Company revenues attributable to oncology information systems were analyzed to estimate segment-specific revenues, followed by extrapolation of regional and global market size based on the estimated market shares of key players. The market forecast was developed by evaluating historical company performance and key market variables over the forecast period.
To learn more about this report,Download Free Sample Report
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
Implementation and switching-cost assessment
Examined implementation timelines, data migration, staff training, workflow redesign, system validation, and integration costs associated with new deployments or vendor replacement.
Helps estimate adoption barriers, identify customer segments with higher implementation readiness, and inform vendor implementation strategies.
EHR integration and interoperability assessment
Assessed integration requirements between oncology information systems and EHRs, PACS, laboratory, pathology, pharmacy, and treatment delivery systems. Examined interoperability needs for exchanging patient, diagnostic, and treatment data.
Highlights integration requirements that influence purchasing decisions and identifies opportunities to improve care coordination.
Oncology software pricing assessment
Assessed pricing structures for oncology information systems, including subscription-based, perpetual-license, and enterprise licensing models. Compared pricing considerations across medical, radiation, and surgical oncology software.
Supports pricing strategy development and identifies models aligned with provider purchasing preferences and budget constraints.
Frequently Asked Questions About This Report
The U.S. oncology information systems market size was estimated at USD 900.29 million in 2024 and is expected to reach USD 963.88 million in 2025.
The U.S. oncology information systems market is expected to grow at a compound annual growth rate of 7.56% from 2025 to 2033 to reach USD 1.73 billion by 2033.
The medical oncology segment dominated the U.S. oncology information systems market and accounted for the largest revenue share of 60.98% in 2024, owing to the rapid advancements in immunotherapy, hormonal therapy, and targeted therapy for effectively treating various cancers.
The software segment dominated the U.S. oncology information systems market and accounted for the largest revenue share of 73.64% in 2024, owing to healthcare providers' rising adoption of radiology imaging management solutions. These software solutions facilitate the exchange of patient information across healthcare organizations to create a bridge between practitioners and radiology centers, which helps improve the safety and efficiency of cancer treatment.
Key factors driving the U.S. oncology information systems market growth include the growing prevalence of cancer among various demographics, the rising demand for advanced innovative oncology information systems (OIS), increased R&D activities, and AI-driven innovation.
About the Author(s)
Healthcare IT Research Team
Healthcare · Healthcare ITThis report was authored by the healthcare it research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the healthcare it segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.